Effect of Dexmedetomidine on Cardiac Surgery Patients

J Cardiovasc Pharmacol. 2023 Feb 1;81(2):104-113. doi: 10.1097/FJC.0000000000001384.

Abstract

Dexmedetomidine, an alpha-2 adrenoreceptor agonist that is widely used as a sedative medication, is becoming more and more attractive in clinical application on cardiac surgery patients. In this review, we aim to summarize and discuss both retrospective studies and clinical trials regarding the effect of dexmedetomidine on patients who underwent cardiac surgery (including coronary artery bypass grafting, valve surgery, aortic surgery, percutaneous coronary intervention, and so on), which illustrates that the clinical effects of dexmedetomidine could effectively reduce mortality, major complications, and the intensive care unit and hospital length of stay without comprising safety. In addition, inconsistent results from both retrospective studies and clinical trials have also been demonstrated. Although the effectiveness and safety of dexmedetomidine on cardiac surgery patients is suggested, high-quality clinical trials are needed for further verification.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiac Surgical Procedures* / adverse effects
  • Coronary Artery Bypass
  • Dexmedetomidine* / adverse effects
  • Humans
  • Hypnotics and Sedatives
  • Retrospective Studies

Substances

  • Dexmedetomidine
  • Hypnotics and Sedatives